GSK Says European Commission Approved Exdensur as Add-on Severe Asthma, Chronic Rhinosinusitis Treatment
MT Newswires Live
Feb 17
GSK (GSK) said Tuesday that the European Commission has approved Exdensur as an add-on maintenance treatment for severe asthma with type 2 inflammation and as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with chronic rhinosinusitis with nasal polyps.
The Commission's approval was based on data from the Swift and Anchor phase 3 trials, in which each of the four trials achieved their primary or co-primary endpoints "with statistically significant and clinically meaningful results," the company said.
Shares of the company were up 2.7% in early Tuesday trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.